MedTrace Logo

Dietary Supplements Among Cancer Patients: Tolerance, Impact on Medications, and Potential Drug Interactions

NCT07670234 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-06-26

No results posted yet for this study

Summary

The goal of this observational study is to To assess the prevalence and patterns of dietary supplement use among patients with cancer and to analyze the impact of these supplements in the context of anticancer medical treatments, including chemotherapy, targeted therapies, hormone therapy, and immunotherapies.

The main questions it aims to answer :

* What is the prevalence of dietary supplement use among cancer patients, and what is their tolerance profile?
* Are there any potential drug interactions between dietary supplements and anticancer medications?

Participants will:

* Provide sociodemographic information, including age, sex, educational level, and other relevant characteristics.
* Report their use of dietary supplements, including the types of supplements consumed (e.g., vitamins, minerals, herbal products), dietary practices, frequency and duration of use, and reasons for consumption (e.g., medical recommendation or self-medication).
* Report any perceived adverse effects related to dietary supplement use to assess tolerance.
* Allow the collection of relevant clinical data from their medical records, including cancer type, ongoing anticancer treatments, and treatment-related adverse effects.

Conditions

  • Cancer (Solid Tumors)
  • Interaction Drug Food

Interventions

BEHAVIORAL

Dietary Supplement Use Assessment

Participants will complete a structured face-to-face questionnaire on dietary supplement use, reasons for Use, frequency and duration of use, perceived adverse effects, and concomitant anticancer treatments.

Sponsors & Collaborators

  • Centre Mohammed VI de la Recherche et de l'Innovation (CM6RI)

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • Morocco

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07670234 on ClinicalTrials.gov